Lung Cancer Chief Editor
Ravi Salgia, MD, PhD
Ravi Salgia, MD, PhD, is the City of Hope Professor and Chair in the Department of Medical Oncology and Therapeutics Research. He is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and Associate Director of Clinical Services. Dr. Salgia was a tenured professor of medicine, pathology and dermatology, and the Director of the Thoracic Oncology Program, and Aerodigestive Tract Program Translational Research Lab in the Section of Hematology/Oncology at the University of Chicago Medical Center in Illinois. Dr Salgia was also an attending physician in the Department of Medicine, Section of Hematology/Oncology, University of Chicago. Dr Salgia is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, and International Association for the Study of Lung Cancer, among others. He was also a member of the Committee on Cancer Biology and Clinical Trials Review Committee at the University of Chicago. Dr Salgia’s research interests focus on novel therapeutics against lung cancer. He has been an invited lecturer to more than 300 symposia and seminars. Dr Salgia has been honored with numerous awards, including recently being named one of the Top Doctors in America. Dr Salgia is a member of the editorial board for the Journal of Carcinogenesis, Update on Cancer Therapeutics, and Current Women’s Health Reviews. He also serves as associate editor for the Journal of Environmental Pathology, Toxicology, and Oncology. He has authored or coauthored more than 100 peer-reviewed publications, 125 abstracts, and 30 book chapters. Dr Salgia earned a medical degree from Loyola University School of Medicine in Chicago, Illinois, where he also obtained a doctorate of philosophy. He did his internship/residency in Internal Medicine at the Johns Hopkins Hospital. He also did his Medical Oncology Fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. He was on faculty at the DFCI for a decade before moving to the University of Chicago.
Lung Cancer Editorial Board
Raphael Bueno, MD
Dr. Bueno is the Associate Chief of Thoracic Surgery at the Brigham and Women’s Hospital and an Associate Professor of Surgery at Harvard Medical School. Dr. Bueno is a busy clinical surgeon with expertise in the surgical management of complex lung cancer. Dr. Bueno is also a funded investigator who has been working in the field of prognosis and diagnosis of thoracic malignancies. He has a particular interest in developing diagnostic and prognostic tests for patients with lung cancer. He has been a member of the Cancer and Leukemia Group B cooperative group for clinical and translational cancer research for the past decade and has participated in several multi-center research efforts through this and other organizations.
Nicholas Campbell, MD
Dr. Nicholas Campbell earned his medical degree at the Medical College of Georgia. He then completed his residency in Internal Medicine and then fellowship in Medical Oncology both at the University of Chicago where he served as Chief Fellow. Dr. Campbell is now a Clinical Assistant Professor at the University of Chicago teaching affiliate hospital, Northshore University. Dr. Campbell’s clinical research interests include novel therapeutics, trial development, and database management in Thoracic Oncology.
Sanja Dacic, MD, PhD
Sanja Dacic, MD, PhD, is associate professor of pathology and Director of FISH and Developmental Laboratory at the University of Pittsburgh Medical Center. Dr Dacic received her medical degree and a doctor of philosophy degree with a thesis on the EGFR signaling pathway in lung carcinomas at the University of Zagreb, Croatia. She completed her residency training at the University of Pittsburgh and joined the faculty immediately after her fellowship in surgical pathology. She started her career in diagnostic pulmonary pathology and has been involved in many basic and translational research projects on molecular profiling of lung carcinomas that resulted in more than 100 peer-reviewed scientific articles and book chapters,. She is a member of the pathology committee for the International Association for Study of Lung Cancer (IASLC) and a member of International Mesothelioma Panel. Dr. Dacic serves as a Deputy Chief Editor of the Archives of Pathology and Laboratory Medicine, and is the editorial board member for American Journal of Clinical Pathology and Advances in Anatomic Pathology. Dr. Dacic is a recipient of Arthur Purdy Stout Prize in 2011 for her research contributions that have had a major impact on diagnostic pathology.
Phillip Dennis, MD, PhD
Dr Phil Dennis is currently Chair, Department of Oncology, Johns Hopkins Bayview Medical Center in Baltimore, MD. Dr. Phillip Dennis attended the University of Virginia as an Echols Scholar and obtained his PhD and MD degrees from New York University as part of the Medical Scientist Training Program. Dr. Dennis completed training in Internal Medicine and Medical Oncology at Johns Hopkins and joined the NCI as a tenure track investigator in 1999. Since then, Dr. Dennis’ scientific and clinical interests have focused on studying signal transduction pathways that contribute to formation, maintenance, and therapeutic resistance of lung cancer. Dr. Dennis became a Senior Investigator in the Medical Oncology Branch in 2006. Dr. Dennis currently heads the Signal Transduction Section in the Medical Oncology Branch. Dr. Dennis is a recipient of the Alton Ochsner Award Relating Smoking and Health and an NIH Merit Award, and was elected to the American Society for Clinical Investigation in 2007.
Gregory Otterson, MD
Dr. Otterson is Professor in the College of Medicine at The Ohio State University James Comprehensive Cancer Center. Dr. Otterson is broadly interested in improving the care and understanding of thoracic malignancies (adenocarcinoma, squamous carcinoma, large cell carcinoma, never-smoking adenocarcinoma, small cell lung cancer, mesothelioma and thymic cancers). His research centers around the genetic and epigenetic changes in lung cancers, particularly microRNAs. Therapeutically, he is interested in understanding how better to target specific therapies to specific patients – i.e. understanding which patients will respond to which therapeutic maneuvers. Dr. Otterson has active collaborations within OSU, including in the Division of Cancer Genetics (Carlo Croce), the School of Public Health (Mary Ellen Wewers and Amy Ferketich), and the Division of Pulmonary and Critical Care Medicine (Patrick Nana-Sinkam). Outside of OSU, he works with investigators at the University of Minnesota, and also actively works with the Cancer and Leukemia Group B, having been National Principal Investigator on three studies through the Respiratory Committee.
George Simon, MD
Dr George Simon is Professor of Medicine and Section Chief, Translational Research; Department of Thoracic/Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center in Houston, TX. Dr Simon was previously Associate Professor of Medicine and Oncology. Dr. Simon is currently Associate Professor of Medicine and Oncology at the Medical University of South Carolina, Charleston, SC. He also served as the Assistant Director of Clinical Investigation at the Hollings Cancer Center and is the Burtschy Family distinguished endowed chair in Cancer Research. Previously he served as the Director of the Thoracic Oncology Program, Department of Medical Oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. After earning his medical degree from the Christian Medical College and Hospital, Ludhiana in Punjab, India, Dr. Simon completed residencies in internal medicine at the Christina Medical College and Hospital, Punjab, India and St. Joseph’s Hospital, Denver, CO, and a fellowship in medical oncology and hematology at the University of Colorado Health Sciences Center in Denver, CO. Previously, Dr. Simon has served as the director of the mesothelioma research program at the H Lee Moffitt Cancer Center, Tampa, FL. Prior to joining the H Lee Moffitt Cancer Center, Dr. Simon served as the Director of Clinical Investigation in the Division of Hemotology and Oncology at the Denver Health Medical Center, Denver, CO. Dr. Simon has served as a member of the NCCN Non-Small Cell Lung Cancer guidelines panel, American College of Chest Physician, Lung Cancer Guidelines committee and in the thoracic core committee of the South West Oncology Group. He currently serves in the Thoracic Core Committee of the Eastern Cooperative Oncology Group. Dr. Simon is an Ad Hoc reviewer for several panels of the National Institutes of Health, National Cancer Institute, and Department of Defense and also a reviewer for several journals including, Cancer Research, Clinical Cancer Research, Chest, Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology, and Indian Journal of Cancer. He is author of co-author of over 70 peer-reviewed research publications, 13 book chapters and over 65 abstracts.